inflammatory-bowel-diseases

Documents about inflammatory-bowel-diseases

• Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease#872903ClinicalTrials.gov
• A Treat-to-target Strategy Using Pan-enteric Capsule Endoscopy (PCE) in Paediatric Crohn's Disease (CD).#1030312ClinicalTrials.gov
• Modèle ex-vivo des maladies inflammatoires chroniques de l'intestin#624600HAL (France)
• A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686#918814ClinicalTrials.gov
• The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis#982700ClinicalTrials.gov
• Functional Restoration After Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine#833994ClinicalTrials.gov
• Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis#848237ClinicalTrials.gov
• Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis#874970ClinicalTrials.gov
• Impact of a New Plant-based High-energy Oral Nutritional Supplement on Nutritional Outcomes in Malnourished Patients#892516ClinicalTrials.gov
• Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)#866662ClinicalTrials.gov
• First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER study#398713HAL (France)
• The Impact of Medication Belief on Adherence to Infliximab in Patients With Crohn's Disease#833370ClinicalTrials.gov
• PRecisiOn Microbiome Directed ExtensiOn of Anti-TNFα Crohn's Disease ThErapy in Children: The PROMOTE Trial#868893ClinicalTrials.gov
• Integrin β7 sustains ileal humoral immunity and microbial biogeography during chronic TNF-driven ileitis#780579eScholarship
• Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases#908353ClinicalTrials.gov
• The Efficacy of Hyperbaric Oxygen-assisted Treatment for ASUC and Refractory IBD#845780ClinicalTrials.gov
• Estado de la cirugía de la enfermedad inflamatoria en España. Resultado de una encuesta nacional#291430Gestión del Repositorio Documental de la Universidad de Salamanca
• A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects#840110ClinicalTrials.gov
• Are Rates of Colectomies, Resections, Mortalities and Cancer Reduced by Home Monitoring of IBD Patients ?#862648ClinicalTrials.gov
• Cardiovascular Risk in Patients With IBD#803886ClinicalTrials.gov
• Cirugía de la enfermedad inflamatoria intestinal en España: ¿cómo lo estamos haciendo? Resultados iniciales de un registro prospectivo nacional (Registro REIC)#291433Gestión del Repositorio Documental de la Universidad de Salamanca
• Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)#906110ClinicalTrials.gov
• Initial Experience With a Novel Single-Balloon Enteroscopy System in Children With IBD#980131ClinicalTrials.gov
• Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease#802040ClinicalTrials.gov
• Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility#859744ClinicalTrials.gov
• IBD Biomarker Discovery and Validation Platform#969561ClinicalTrials.gov
• Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Treatment of UC#895227ClinicalTrials.gov
• A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease#835171ClinicalTrials.gov
• Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD#863435ClinicalTrials.gov
• Risk factors for immune checkpoint inhibitor colitis: a retrospective multi-center cohort study using electronic health records#620193eScholarship
• Coordinated Interferon-γ/Tumor Necrosis Factor Axis Drives Selective Loss of Activated Enteric Glia in Inflammatory Bowel Diseases / Marvin Bubeck, Klara A. Penkert, Heidi Limberger, Miguel González Acera, Christina Plattner, Svenja Ziegler, Anoohya Muppirala, Patrycja Forster, Manuel Jakob, Reyes Gamez-Belmonte, Lena Erkert, Subhash Kulkarni, Claudia Günther, Raja Atreya, Anja A. Kühl, Ahmed N. Hegazy, Kai Hildner, Zlatko Trajanoski, Britta Siegmund, Markus F. Neurath, Meenakshi Rao, Fränze Progatzky, Dieter Chichung Lie, Christoph Becker, Chiara Romagnani, Leif S. Ludwig, Christoph S.N. Klose, Jay V. Patankar#675554Deutsche Nationalbibliothek